INDRAMEDCO · Health Care · 2026-08-21

Indraprastha Medical Corporation Ltd

Stage 4 · wk 14In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹369.7
-1.88% today
₹3,389 Cr · Small cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.

Visit company website →
P/E (TTM)
19.6
Forward 15.9
Earnings Growth (YoY)
+1.8%
Revenue +9.3%
ROE
+27.5%
Profit margin +12.4%
Dividend Yield
1.21%
P/B 5.5
vs 52W High
-40.6%
₹349.5 lo₹622.8 hi
40.6% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 14
1w13w26w
Week 14 — established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-11.2%
200 DMA: ₹416.3 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.43x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
→
MA20 flat · +0.5% vs MA50 -0.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
55.6%
20d Δ
-7.4pp
1M return
-2.8%
3M return
+2.0%
Industry Stage-2 % · last 20 days
Industry has 15 Stage 2 leaders. See Hospitals & Diagnostic Centres Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 36w
S2 14w
S2 28w
S4 13w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 36w → S3 9w → S2 14w → S3 3w → S2 28w → S3 7w → S4 7w → S1 7w → S2 11w → S3 1w → S2 10w → S3 4w → S4 12w → S1 5w → S4 13w current
Total tracked: 167 weeks across 15 stage runs.
1M
+0.8%
3M
+3.0%
6M
-11.5%
YTD
-17.0%
1Y
-20.2%
Scan Membership
Breakout Watch
Latest: 2025-10-13
4 appearances in last 60 days. First seen: 2024-04-08.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S4
Wk 14 · Vol —x
2026-08-20S4
Wk 13 · Vol —x
2026-08-19S4
Wk 13 · Vol —x
2026-08-18S4
Wk 13 · Vol —x
2026-08-17S4
Wk 13 · Vol —x
2026-08-14S4
Wk 13 · Vol —x
2026-08-13S4
Wk 12 · Vol —x
2026-08-12S4
Wk 12 · Vol —x
2026-08-11S4
Wk 12 · Vol —x
2026-08-10S4
Wk 12 · Vol —x
2026-08-07S4
Wk 12 · Vol —x
2026-08-06S4
Wk 11 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹376.8
200 DMA
₹416.3
52W High
₹622.8
52W Low
₹349.5
5D Low
₹369
Resistance levels (recent highs)
20d High
₹390.8
60d High
₹402.2
120d High
₹439
250d High
₹622.8
Next resistance
+5.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.